



DE-RISKING BIOTECH INVESTMENTS WITH OPERATIONAL DUE DILIGENCE

Amin Jagani

Managing Partner

CONTENTS

- The Problem: The Venture Capital Operational Blindspot
- The Solution: HYGEIA Group in a Nutshell
- About Us: Founder & Managing Partner
- Services: Our Productized Services for Investors
- Case Study 1 – Driving a Successful Exit
- Case Study 2 – Interim Leadership Turnaround
- Our Therapeutic Expertise
- Why Partner with HYGEIA
- Next Steps

THE GAP IN YOUR DUE DILIGENCE

Venture Capital Operational Blindspot

VC'S OPERATIONAL BLIND SPOTS

Flawed Diligence

- Founders' projections are accepted at face value. Unrealistic budgets, flawed protocols, and poor vendor selections.

Portfolio Fires

- A key asset goes off the rails. Enrollment stalls, CROs underperform, and timelines slip, putting the entire investment at risk

Founder-Operator Gap

- Brilliant scientific founders lack the C-suite operational experience to scale, manage global trials, and deploy capital efficiently.

Portfolio Black Box

- Lack of standardized, real-time KPIs makes it impossible to truly know the operational health of an asset until it's too late

THE SOLUTION:

HYGEIA provides the operational due diligence and portfolio oversight that bridges the gap between promising science and a valuable clinical asset. We are the operational partner for biotech investors, embedding the deep clinical execution expertise you need to de-risk investments pre-deal and protect them post-deal.

OUR FOUNDER & MANAGING PARTNER

20+ years leading global clinical programs, now focused on de-risking biotech investments.

- Former Director of Clinical Project Management at PAREXEL, managing portfolios with budgets over \$0.5B.
- Post-Graduate Training, Harvard Medical School (Cancer Genomics & Precision Oncology).
- Accredited in Value Investing & Portfolio Management, Ivey Business School.
- MBA (Corporate Finance), Queen's University; Registered Pharmacist.
- Author of "*The Profit Pill*," a guide to value investing in pharma/biotech



Amin Jagani

OUR PRODUCTIZED SERVICES

Investor Solutions

The bottom of the slide features several overlapping, wavy, organic shapes in various shades of blue and purple, creating a modern, fluid design element.

SERVICES FOR INVESTORS

Due-Diligence Sprint (\$40k+):

- A 4-week deep dive on one lead asset. Identify deal-killing operational flaws before you sign the term sheet

Regulatory-to-Reimbursement Blueprint (\$55k+):

- De-risk the commercial exit by mapping the end-to-end strategy from IND to market access and reimbursement

Portfolio Health & Performance Intelligence (\$45k setup + \$4k/mo):

- Dashboard and monthly executive briefings. [Pain Point: Portfolio Black Box]

Interim Clinical Leadership (\$65k/mo):

- Embedded CXO to turnaround a struggling trial. Take control of a struggling asset and protect your capital.

Leadership Workshop Series (\$22k/session):

- Upskill your portfolio company CEOs/CROs to bridge the common founder-operator gap

M&A Clinical Integration Package (\$120k+):

- Post-merger integration for roll-up strategies. Maximize the value of your roll-up strategy

CASE STUDY #1

DRIVING A SUCCESSFUL EXIT

DRIVING A SUCCESSFUL EXIT

Background:

- Publicly traded biotech with two pediatric glioblastoma Phase 2 studies (Precision Oncology, Adaptive Design).

Challenge:

Managed a portfolio of two complex studies and oversaw CRO/vendors as fractional CXO.

HYGEIA Solution:

- Restructured the vendor management protocol, identifying and replacing an underperforming data supplier. Implemented a new KPI dashboard that provided the board with the first-ever real-time view of enrollment, leading to a critical protocol amendment that accelerated recruitment by 30%

Result:

- Phase 2 PoC data: ORR 64%, CBR 91%.
- Stock price jumped from \$7.97 to \$26.67 post press-release of topline Phase IIb data.
- Company acquired by large pharma, providing a major liquidity event for VC.

CASE STUDY #2

Interim Leadership Turnaround



INTERIM LEADERSHIP TURNAROUND

Background:

- \$35M Series B raised for portfolio company for Phase 2 Trial in Diabetic Retinopathy. Trial mismanaged and struggled to recruit with enrollment delayed by 6 months. End of Phase II Meeting with FDA delayed.

Challenge:

- CRO had cycled through 4 project managers in 12 months. Real-time metrics were unavailable. Portfolio company Founder contacted CEO of CRO threatening to pull the study.

HYGEIA Solution:

- Deployed as interim Project Director. Immediately renegotiated the master services agreement with the underperforming CRO, clawing back \$250k in fees and tying all future payments to specific performance metrics. Re-trained the clinical team on the revised protocol, leading to the trial exceeding its revised enrollment targets by 15%

Result:

- This intervention salvaged an asset valued at \$35M and positioned it for a strategic partnership, preserving the full value of the Series B investment.

OUR THERAPEUTIC EXPERTISE

Deep Expertise in Complex Modalities & Therapeutics Areas



OUR THERAPEUTIC EXPERTISE

- Precision Oncology & Cancer Genomics
- Cell & Gene Therapy
- Rare Diseases / Orphan Drug Research
- Central Nervous Systems
- Cardiovascular and Critical Care
- Immunology, Hematology, Infections
- Women's Health
- Dermatology
- Gastroenterology
- Ophthalmology

WHY HYGEIA IS UNIQUE



A UNIQUE BLEND OF OPERATIONAL, SCIENTIFIC, AND FINANCIAL EXPERTISE

Differentiators:

CRO Operator Experience: *We've managed the P&L and delivered the global trials you're funding*

Scientific Depth: *Harvard-trained in cutting-edge modalities (Cancer Genomics, Precision Oncology).*

Investor's Mindset: *We speak the language of ROI, capital allocation, and exit strategies.*

Productized Offerings: *Clear, fixed-fee services with defined outcomes, no open-ended consulting.*

Exclusive Investor Focus: *We are 100% aligned with your goals because we only work for the people writing the checks.*

LET'S START DE-RISKING YOUR NEXT INVESTMENT

Schedule a 30-minute confidential briefing to discuss your current deal flow or portfolio challenges.

You can also request our complimentary 'VC Due Diligence Checklist' to use on your next deal.

Amin Jagani

mjagani@hygeiagroupinc.com

Phone: + 905 – 841 - 4752